Pre-op Pembro + Radiation Therapy in Breast Cancer (P-RAD)
Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
This research trial is studying a combination of neoadjuvant radiotherapy (RT), immunotherapy
(pembrolizumab) and chemotherapy for lymph node-positive, triple negative (TN) or hormone
receptor positive/HER2-negative breast cancer.
The names of the study interventions involved in this study are:
- Radiation Therapy (RT)
- Immunotherapy: Pembrolizumab (MK-3475)
- Chemotherapies:
- Paclitaxel
- Doxorubicin (also called Adriamycin)
- Cyclophosphamide
- Carboplatin (optional, and in TN only)
- Capecitabine (optional, and in TN only)
Phase:
Phase 2
Details
Lead Sponsor:
Alice Ho
Collaborators:
Breast Cancer Research Foundation Merck Sharp & Dohme Corp. Translational Breast Cancer Research Consortium